Women-Only Trial Supports Self-Expanding TAVR as the Way to Go

Women-Only Trial Supports Self-Expanding TAVR as the Way to Go

(MedPage Today) -- Transcatheter aortic valve replacement (TAVR) with a self-expanding valve still worked out better, at least in terms of hemodynamics, in the first head-to-head device trial exclusively in women. Among older women with symptomatic...

SMART update: Self-expanding TAVR valves still linked to superior durability after 3 years

These three-year data represent a major update to one of the more noteworthy TAVR trials in recent memory.

EuroPCR 2026: SMART trial three-year data demonstrate superiority for Evolut TAVI system

Howard C Herrmann Medtronic today released the three-year results of the SMall Annuli Randomized To Evolut or Sapien (SMART) trial, the largest international head-to-head comparative trial of transcatheter aortic valve implanation (TAVI). In patients with aortic stenosis (AS) and a small aortic annulus, results showed all individual and composite haemodynamic measures continue to be superior at three years for Evolut TAVR compared to Sapien (Edw…